Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.31 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.31 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4575757 | 0.79 | USP7 (0.57) | USP7NOTUMHPGDCA1CA2 | |
| SCHEMBL4574780 | 0.75 | S1PR1 (0.39) | USP7BRD4CA1CA2CA9 | |
| SCHEMBL23291919 | 0.73 | AOC3 (0.44) | BRD4HPGDALDH1A1KDM4EHDAC1 | |
| SCHEMBL14126224 | 0.72 | HDAC1 (0.47) | BRD4KDM4EHDAC1HDAC8HDAC6 | |
| SCHEMBL12578825 | 0.72 | HDAC1 (0.46) | KDM4EHDAC1HDAC8HDAC6ENPP3 | |
| SCHEMBL2387102 | 0.70 | CA1 (0.60) | CA1CA2ALDH1A1KDM4E | |
| SCHEMBL16761870 | 0.69 | NOTUM (0.47) | BRD4NOTUMCYP2A6 | |
| SCHEMBL21774317 | 0.69 | MAPT (0.40) | BRD4HPGDALDH1A1KDM4EHDAC1 | |
| SCHEMBL4576107 | 0.69 | DRD2 (0.48) | BRD4 | |
| SCHEMBL14277967 | 0.67 | NPC1 (0.51) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319104-B2 | hPPARs activators | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-15 | — | — | US | disclosed |
| US-20050137212-A1 | Hppars activators | SMITHKLINE BEECHAM CORPORATION | 2005-06-23 | — | — | US | disclosed |
| EP-1480957-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-01 | — | — | EP | disclosed |
| WO-2003074495-A1 | HPPARS ACTIVATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137212-A1 | Hppars activators | PPARG, PPARA, PPARD | USP7 2535/4885BRD4 1800/4885NOTUM 1759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.